CAM
RNAM

Cormorant Asset Management’s Avidity Biosciences RNAM Stock Holding History

Cormorant Asset Management’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-300,000
Closed -$13.1M – 41
2025
Q3 		$13.1M Buy
300,000
+100,000
+50% +$4.04M 0.9% 26
2025
Q2 		$5.68M Sell
200,000
-200,000
-50% -$5.96M 0.42% 37
2025
Q1 		$11.8M Sell
400,000
-650,000
-62% -$20.2M 0.89% 27
2024
Q4 		$30.5M Hold
1,050,000
– – 1.68% 17
2024
Q3 		$48.2M Buy
1,050,000
+625,000
+147% +$27.1M 2.56% 11
2024
Q2 		$17.4M Buy
+425,000
New +$12.2M 1% 30
2023
Q4 		– Sell
-1,762,115
Closed -$11.2M – 54
2023
Q3 		$11.2M Sell
1,762,115
-850,000
-33% -$7.32M 0.66% 33
2023
Q2 		$29M Hold
2,612,115
– – 1.62% 15
2023
Q1 		$40.1M Sell
2,612,115
-150,000
-5% -$3.3M 2.64% 10
2022
Q4 		$61.3M Buy
2,762,115
+750,000
+37% +$11.2M 4.1% 5
2022
Q3 		$32.9M Hold
2,012,115
– – 2.3% 14
2022
Q2 		$29.2M Hold
2,012,115
– – 2.21% 13
2022
Q1 		$37.2M Hold
2,012,115
– – 2.85% 11
2021
Q4 		$47.8M Sell
2,012,115
-150,000
-7% -$3.58M 2.84% 10
2021
Q3 		$53.3M Sell
2,162,115
-66,552
-3% -$1.45M 2.16% 14
2021
Q2 		$55.1M Sell
2,228,667
-235,878
-10% -$5.49M 1.87% 14
2021
Q1 		$53.8M Sell
2,464,545
-2
-0% -$49 1.2% 21
2020
Q4 		$62.9M Sell
2,464,547
-49,999
-2% -$1.46M 1.5% 23
2020
Q3 		$69.5M Sell
2,514,546
-1
-0% -$29 2.67% 8
2020
Q2 		$67.8M Buy
+2,514,547
New +$72.5M 2.59% 10

Other funds holding RNAM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Cormorant Asset Management's RNAM Position: Q4 2025 in Review

Cormorant Asset Management sold out of Avidity Biosciences (RNAM) in Q4 2025, closing a stake of 300,000 shares — an estimated $13.1M sold.

Cormorant Asset Management first reported a position in RNAM in Q2 2020 and held it in 20 quarters. The position peaked at $69.5M in Q3 2020. 343 funds tracked by Wall St. Rank hold RNAM as of Q4 2025.

  • Cormorant Asset Management reported no remaining Avidity Biosciences position as of Q4 2025 after selling out during the quarter.
  • Cormorant Asset Management sold 300,000 Avidity Biosciences shares in Q4 2025, an estimated $13.1M.
  • Cormorant Asset Management first reported a position in Avidity Biosciences in Q2 2020 and held it in 20 quarters.
  • Cormorant Asset Management's Avidity Biosciences position peaked at $69.5M in Q3 2020.
  • 343 funds tracked by Wall St. Rank held Avidity Biosciences as of Q4 2025.

Based on Cormorant Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.